Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01760005
Recruitment Status : Active, not recruiting
First Posted : January 3, 2013
Last Update Posted : June 6, 2018
Eli Lilly and Company
Hoffmann-La Roche
Alzheimer's Association
National Institute on Aging (NIA)
Avid Radiopharmaceuticals
Accelerating Medicines Partnership (AMP)
Janssen Research and Development
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.

Condition or disease Intervention/treatment Phase
Alzheimers Disease Dementia Alzheimers Disease, Familial Drug: Gantenerumab Drug: Solanezumab Drug: Matching Placebo (Gantenerumab) Drug: Matching Placebo (Solanezumab) Drug: JNJ-54861911 Drug: Matching Placebo (JNJ-54861911) Phase 2 Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 438 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
Study Start Date : December 2012
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : December 2023

Arm Intervention/treatment
Experimental: Gantenerumab Drug: Gantenerumab
Subcutaneously every 4 weeks at escalating doses
Other Name: RO4909832

Experimental: Solanezumab Drug: Solanezumab
Intravenous infusion every 4 weeks at escalating doses
Other Name: LY2062430

Placebo Comparator: Matching placebo (Gantenerumab) Drug: Matching Placebo (Gantenerumab)
Subcutaneous injection of placebo every 4 weeks

Placebo Comparator: Matching Placebo (Solanezumab) Drug: Matching Placebo (Solanezumab)
Intravenous infusion of placebo every 4 weeks

Experimental: JNJ-54861911 Drug: JNJ-54861911
25 mg daily oral tablet

Placebo Comparator: Matching Placebo (JNJ-54861911) Drug: Matching Placebo (JNJ-54861911)
Daily oral placebo tablet

Primary Outcome Measures :
  1. Assess cognitive efficacy in individuals with mutations causing dominantly inherited AD as measured by change in the DIAN-TU cognitive composite score. [ Time Frame: Baseline and Weeks 52, 104, 156, and 208 ]

Secondary Outcome Measures :
  1. Gantenerumab: Cerebral amyloid imaging using [11C]PiB-PET. [ Time Frame: Baseline and Weeks 52, 104, and 208 ]
  2. Solanezumab: Total Abeta 1-42 (Aβ42) in CSF. [ Time Frame: Baseline, Week 104 ]
  3. JNJ-54861911: CSF amyloid-beta peptide concentration as measured by Abeta 1-42 (Aβ42) in CSF. [ Time Frame: Baseline, Week 208 ]
  4. Change from Baseline in Clinical Measures [ Time Frame: Baseline, week 208 ]
    • Clinical Dementia Rating (CDR), including CDR sum of boxes (CDR-SB) and clinician's diagnostic assessment
    • Geriatric Depression Scale (GDS)
    • Neuropsychiatric Inventory Questionnaire (NPI-Q)
    • Functional Assessment Questionnaire (FAQ)
    • Mini Mental Status Exam (MMSE)

  5. Change from Baseline in Cognitive Measures [ Time Frame: Baseline, week 208 ]
    • International Shopping List Test (12-Item Word List Learning): 3 learning trials, Immediate Recall, 30-min Delayed Recall (CogState)
    • Groton Maze Learning Test: Timed Chase Task, 5 learning Trials, Immediate Recall, 30-min Delayed Recall (CogState)
    • Cogstate Detection Task
    • Cogstate Identification Test
    • Cogstate One Card Learning Test
    • Cogstate One-Back (OBK) Task
    • Behavioral Pattern Separation Object Task
    • Memory Complaint Questionnaire (MAC-Q)
    • Trails A & B
    • Wechsler Memory Scale - Revised (WMS-R) Digit Span
    • Wechsler Adult Intelligence Scale - Revised (WAIS-R) Digit-Symbol Substitution Test
    • Raven's Progressive Matrices (Set A)
    • Category Fluency (Animals & Vegetables)
    • Wechsler Memory Scale Logical Memory I Paragraph Memory (Immediate & Delayed Recall)

Other Outcome Measures:
  1. Safety and Tolerability Outcome Measures [ Time Frame: Baseline, week 208 ]
    • Neurological findings
    • Laboratory test results
    • ECG findings
    • Safety MRIs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Between 18-80 years of age
  • Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have a 50% chance of having an autosomal dominant Alzheimer's disease (ADAD) mutation (e.g. parent or sibling with a known AD-causing mutation)
  • Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset
  • Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)
  • Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning
  • Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.
  • For women of childbearing potential, if partner is not sterilized, subject must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide).
  • Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
  • Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion.

Exclusion Criteria:

  • History or presence of brain MRI scans indicative of any other significant abnormality
  • Alcohol or drug dependence currently or within the past 1 year
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan.
  • History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
  • Anticoagulants except low dose (≤ 325 mg) aspirin.
  • Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.
  • History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.
  • Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.
  • Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.
  • JNJ-54861911 study arm only: Hypopigmentation abnormality of the skin such as vitiligo, other than small localized findings, at baseline dermatological test.
  • JNJ-54861911 study arm only: Subjects with the APP Swedish Mutation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01760005

  Hide Study Locations
United States, Alabama
University of Alabama in Birmingham
Birmingham, Alabama, United States, 35294
United States, California
University of California San Diego Medical Center
La Jolla, California, United States, 92037
USC Keck School of Medicine
Los Angeles, California, United States, 90033
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30329
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
United States, Missouri
Washington University in St. Louis
Saint Louis, Missouri, United States, 63110
United States, New York
Columbia University
New York, New York, United States, 10032
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
Butler Hospital
Providence, Rhode Island, United States, 02096
United States, Texas
Texas Health Hospital
Arlington, Texas, United States, 76011
United States, Washington
University of Washington
Seattle, Washington, United States, 98195
Instituto de Investigaciones Neurologicas Raul Carrea, FLENI
Ciudad Autonoma de Buenos Aire, Argentina, C1428AQK
Australia, New South Wales
Neuroscience Research Australia
Randwick, New South Wales, Australia, 2031
Australia, Victoria
Mental Health Research Institute
Melbourne, Victoria, Australia, 3010
Australia, Western Australia
The McCuster Foundation of Alzheimer's Disease Research
Nedlands, Western Australia, Australia, 6009
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, Brazil, 05403-000
Canada, British Columbia
UBC Hospital
Vancouver, British Columbia, Canada, V6T 2B5
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
McGill Center for Studies in Aging
Verdun, Quebec, Canada, H4H 1R3
CHU de Quebec - Hôpital de l' Enfant Jésus
Québec, Canada, G1J 1Z4
CHU de Toulouse - Hôpital Purpan
Toulouse, Haute Garonne, France, 31059
Hopital Roger Salengro - CHU Lille
Lille, Nord, France, 59037
Groupe Hospitalier Pitie-Salpetriere
Paris cedex 13, Paris, France, 69677
Hopital Neurologique Pierre Wertheimer
Bron cedex, Rhone, France, 69677
CHU de Rouen - Hôpital Charles Nicolle
Rouen, Seine Maritime, France, 76031
Universitaetsklinikum Tubingen
Tübingen, Baden Wuerttemberg, Germany, 72076
LMU-Campus Grosshadern
Muenchen, Bayern, Germany, 81377
St Vincent's University Hospital
Dublin, Ireland, DUBLIN 4
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Brescia, Italy, 25125
Azienda Ospedaliera Universitaria Careggi
Firenze, Italy, 50134
Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Mexico, Distrito Federal, Mexico, 14269
Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
Zapopan, Jalisco, Mexico, 45030
Puerto Rico
University of Puerto Rico, School of Medicine
San Juan, Puerto Rico, 00936
Hospital Clínic I Provincial de Barcelona
Barcelona, Spain, 8036
United Kingdom
The National Hospital for Neurology and Neurosurgery
London, Greater London, United Kingdom, WC1B 3BG
Sponsors and Collaborators
Washington University School of Medicine
Eli Lilly and Company
Hoffmann-La Roche
Alzheimer's Association
National Institute on Aging (NIA)
Avid Radiopharmaceuticals
Accelerating Medicines Partnership (AMP)
Janssen Research and Development
Study Director: Randall J Bateman, MD Washington University School of Medicine

Additional Information:
Responsible Party: Washington University School of Medicine Identifier: NCT01760005     History of Changes
Other Study ID Numbers: DIAN-TU-001
The Alzheimer's Association ( Other Grant/Funding Number: DIAN TTU-12-243040 )
U01AG042791 ( U.S. NIH Grant/Contract )
2013-000307-17 ( EudraCT Number )
R01AG046179 ( U.S. NIH Grant/Contract )
REec-2014-0817 ( Registry Identifier: Spanish Clinical Studies Registry )
The Alzheimer's Association ( Other Grant/Funding Number: DIAN-TU Tau-15-347219 )
The Alzheimer's Association ( Other Grant/Funding Number: DIAN-TU NG-16-434362 )
R56AG053267 ( U.S. NIH Grant/Contract )
GHR Foundation ( Other Grant/Funding Number: File 4401 )
First Posted: January 3, 2013    Key Record Dates
Last Update Posted: June 6, 2018
Last Verified: June 2018

Keywords provided by Washington University School of Medicine:
Alzheimer's Disease
Genetic Mutation
Dominantly Inherited Alzheimer's Disease
Dominantly Inherited Alzheimer's Network
Autosomal Dominant Alzheimer's Disease
Early Onset Alzheimer's Disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs